and associated resources

Abstract Quantitative structure activity-relationship (QSAR)

License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Antibodies appear to be the first line of defence in the adaptive immune response of vertebrates and thereby are involved in a multitude of biochemical mechanisms, such as regulation of infection, autoimmunity, and cancer. It goes without saying that a full understanding of antibody function is required for the development of novel antibody-interacting drugs. These drugs are the Antibody Drug Conjugates (ADCs), which are a new type of targeted therapy, used for example for cancer. They consist of an antibody (or antibody fragment such as a single-chain variable fragment [scFv]) linked to a payload drug (often cytotoxic). Because of the targeting, the side effects should be lower and give a wider therapeutic window. Overall, the underlying principle of ADCs is to discern the delivery of a drug that is cytotoxic to a target that is cancerous, hoping to increase the antitumoural potency of the original drug by reducing adverse effects and side effects, such as toxicity of the cancer target.This is a pioneering field that employs state-of-the-art computational and molecular biology methods in the fight against cancer using ADCs. 1.

tho th ar st en w-

Bioinformatics approaches for functional annotation of membrane proteins